Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has entered into a collaboration to establish a joint lab in Cambridge, UK, with Cancer Research Technology, the commercial arm of Cancer Research UK.
The new laboratory will be the first partnership of its kind of both organizations, and will focus on the discovery and development of biologic cancer treatments over an initial five-year period.
{iframe}http://www.thepharmaletter.com/article/astrazeneca-s-medimmune-to-collaborate-on-new-oncology-biologics-lab-with-cancer-research-uk{/iframe}